Figure 7: Improved gait quality of GRMD dogs injected with rAAV2/8-Spc5.12-cMD1 by the IV route.

The global gait quality was determined twice a month using Locometrix and analysed by a discriminant analysis of seven accelerometric variables. The curves represent the evolution of the mean gait index with 95% confident intervals (shaded areas) in healthy dogs (n=9, including animals from retrospective cohorts, green curve), untreated GRMD dogs (n=25, including animals from retrospective cohorts, red curve) and GRMD dogs injected intravenously with rAAV2/8-Spc5.12-cMD1 at 2 × 10¹³ vg kg⁻¹ (n=3, light grey curve) or 1 × 10¹⁴ vg kg⁻¹ (n=5, dark grey curve). F1 and F2 represent the two axes used to plot data during discriminant analysis. An additional axis corresponding to the age in months was also calculated and represented. The discriminant analysis (see details in the Methods section) allows a statistical evaluation to test the probability that the gait of the treated animals was similar (P>0.95) to those of healthy dogs or of untreated GRMD dogs. The result of this statistical evaluation was represented as a colour code, using a green plot when the gait was found similar to those of healthy dogs, a red plot when similar to those of untreated GRMD dogs and yellow when the gait was considered as intermediate between healthy and untreated GRMD dogs.